216574-50-4Relevant academic research and scientific papers
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, furyl, and pyrrolyl ureas
Redman, Aniko M,Johnson, Jeffrey S.,Dally, Robert,Swartz, Steve,Wild, Hanno,Paulsen, Holger,Caringal, Yolanda,Gunn, David,Renick, Joel,Osterhout, Martin,Kingery-Wood, Jill,Smith, Roger A.,Lee, Wendy,Dumas, Jacques,Wilhelm, Scott M.,Housley, Timothy J.,Bhargava, Ajay,Ranges, Gerald E.,Shrikhande, Alka,Young, Deborah,Bombara, Michael,Scott, William J.
, p. 9 - 12 (2001)
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range. (C) 2000 Elsevier Science Ltd.
RAF KINASE INHIBITORS
-
Page/Page column 11; 18, (2008/12/06)
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Inhibition of p38 kinase activity by aryl ureas
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
